SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.0099454 USD and is down -2.36 over the last 24 hours. It is currently trading on 1896 active market(s) with $2,532,309,467.05 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs steep decline alongside a broader crypto selloff has pushed it below the closely watched $1 level, prompting fears of further losses and debate over whether support will hold. Bearish traders point to weak momentum and market-wide pressure, while long-term holders are buying or accumulating the dip.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,631. The last known price of Bitcoin is 68,229.80907922 USD and is down -4.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $42,739,134,877.94 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff toward the $66,000$68,000 area and repeated tests of support dominate discussion, with bearish traders warning of further losses while dip-buyers point to extreme fear and oversold conditions as signs a rebound may be near. Traders also cite rising yields, ETF outflows and competition for capital from a potential Anthropic IPO as possible pressures, though the conversation does not establish a single confirmed cause.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,079,719,016.041028 in circulation. The last known price of Algorand is 0.08513994 USD and is down -2.94 over the last 24 hours. It is currently trading on 586 active market(s) with $61,102,468.95 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

Algorands price weakness is driving debate over whether the pullback is a buying opportunity or a sign of further downside. Bulls say they are accumulating dips and see support holding, while bearish traders warn that the prolonged decline may continue.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

A nationwide FAA ground stop after air-traffic-control communications failures disrupted departures and weighed on airline shares, including American Airlines. Traders debated whether the outage signaled a larger cyber or technology problem, but those theories remain unsubstantiated; the cause reported was a communications issue, with the ground stop later lifted.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Discussion centers on lonvo-zs reported durable HAE results after a one-time CRISPR treatment and its FDA priority review, with the community focused on the March 2027 decision. Many see the data as promising but are frustrated by the share decline; others point to market and biotech weakness, commercial execution risks, or suspected short-selling as possible factors.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd.

Teva- Pharmaceutical Industries Ltd. - ADR

Tevas earnings beat and higher 2026 outlook, supported by growth in its innovative brands, are fueling bullish momentum and fresh-high chatter. Traders are also watching R&D pipeline updates and the pending FDA decision on at-home Igalmi, while some debate whether the sharp run-up can continue.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnsons run to fresh highs and its appeal as a defensive healthcare holding are drawing attention, with traders also discussing oncology pipeline developments. Repeated speculation that J&J could acquire Sellas is unconfirmed, and some traders question whether the rally has run too far.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA decision on ivonescimab for EGFR-mutated lung cancer is driving a high-stakes binary-event trade. Traders are divided over the strong progression-free-survival results and favorable overall-survival trend versus the missed statistical-significance threshold for overall survival, with the uncertainty fueling volatile positioning and concern about a rejection.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is drawing attention after third-quarter results topped expectations, with traders reacting to a strong contribution from Alani Nu and international growth. The upbeat read is tempered by concerns about declining sales for the core Celsius brand and compressed margins.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigels Q3 report sparked a sharp selloff as an earnings miss and concerns about spending outweighed stronger product sales. Traders are divided: some see the early VEPPANU launch and upcoming R289 data as reasons for optimism, while others question whether growth will meet expectations.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Greendays1234

Greendays1234